BRAHMS AKTIENGESELLSCHAFT Patent applications |
Patent application number | Title | Published |
20120122233 | METHOD FOR RISK STRATIFICATION IN STABLE CORONARY ARTERY DISEASE - An in vitro method for the risk stratification of patients with stable arteriosclerosis, especially stable coronary artery disease, is disclosed wherein the concentration of procalcitonin is determined in the circulation of such patients using a highly sensitive PCT assay, and wherein within the range of PCT concentrations in the typical normal range of healthy individuals cutoff values are defined which distinguish groups of individual patients with stable arteriosclerosis in accordance with personal cardiac risk, and patients are allotted to one of said risk groups on the basis of their individual PCT concentrations. | 05-17-2012 |
20110039343 | METHOD FOR THE IDENTIFICATION OF PATIENTS IN NEED OF THERAPY HAVING MINOR COGNITIVE DISORDERS AND THE TREATMENT OF SUCH PATIENTS - A method for the identification of patients in need of therapy and for the preventive treatment of such patients having minor cognitive disorders, wherein an increased risk can be determined for said patients to develop clinically manifested Alzheimer's disease during a preceding risk stratification as a result of an increase in circulation-relevant peptide biomarkers measurable in the circulation of said patients, using drugs that comprise one or more active ingredients of cardiovascular agents, which are selected from the group consisting of ACE inhibitors, angiotensin II receptor antagonists, betablockers and blood pressure-lowering diuretics and the combinations thereof, or using drugs comprising one or more ANP receptor antagonists or one or more adenosine receptor antagonists. | 02-17-2011 |
20110039283 | DIAGNOSIS AND RISK STRATIFICATION USING NT-proET-1 - The invention relates to a method for the diagnosis and/or risk stratification of cardiac diseases and diseases of the respiratory tract and lungs. According to said method, the free fragment N-terminal proEndothelin (NT-proET-1; AS 18-52 of the pre-proET according to FIG. | 02-17-2011 |
20110008911 | DIAGNOSTIC METHOD FOR DISORDERS USING COPEPTIN - The use of copeptin as diagnostic marker for the determination of the release of vasopressin, especially in connection with disorders associated with non-physiological alterations of vasopressin release from the neurohypophysis, especially for detection and early detection, diagnosing and monitoring of the course of cardiovascular diseases, renal and pulmonary diseases as well as shock, including septic shock, sepsis and diseases/disorders of the central nervous system and neurodegenerative diseases. | 01-13-2011 |
20100209433 | METHODS FOR THE DIAGNOSIS AND FOR THE TREATMENT OF CRITICALLY ILL PATIENTS WITH ENDOTHELIN, ENDOTHELIN AGONISTS AND ADRENOMEDULLIN ANTAGONISTS - The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM but insufficient levels of pro-END immunoreactivities with a medicament comprising vasoconstrictive endothelin or its precursors, and/or endothelin agonists or adrenomedullin antagonists is provided. | 08-19-2010 |
20100159474 | PROGNOSIS AND RISK ASSESSMENT IN PATIENTS SUFFERING FROM HEART FAILURE BY DETERMINING THE LEVEL OF ADM AND BNP - The present invention relates to a method for prognosis of an outcome or assessing the risk of a patient suffering from heart failure and/or shortness of breath, comprising the determination of the levels of ADM or fragments thereof or its precursor or fragments thereof and BNP or fragments thereof or its precursor or fragments thereof in said sample of said patient. | 06-24-2010 |
20100143953 | DIAGNOSIS AND RISK STRATIFICATION OF CARDIAC INSUFFICIENCY BY MEANS OF NATRIURETIC PEPTIDES FOR NYHA I PATIENTS - The invention relates to a method for the diagnosis, and/or risk stratification, and/or outcome prognosis of cardiac insufficiency for NYHA I patients, wherein a determination of the proANP marker, NT-proANP marker, or fragments or partial peptides thereof is carried out parallel to a determination of BNP, proBNP, and/or NT-proBNP on patients to be examined. | 06-10-2010 |
20100093012 | DIAGNOSIS AND RISK STRATIFICATION OF CARDIAC INSUFFICIENCY USING NEUROPHYSIN - The invention relates to a method for the diagnosis and/or risk stratification of cardiac insufficiency, according to which the marker neurophysin or a fragment or partial peptide thereof is determined on patients to be examined. The invention also relates to advantageous marker combinations containing neurophysin, and to a diagnostic device and a kit for carrying out the method. | 04-15-2010 |
20100062463 | IN VITRO MULTIPARAMETER DETERMINATION METHOD FOR THE DIAGNOSIS AND EARLY DIAGNOSIS OF NEURODEGENERATIVE DISORDERS - In vitro multiparameter method for the diagnosis and early diagnosis, for determination of the severity and for assessing the course and prognosis of neurodegenerative disorders, in which the concentrations of at least two different vasotropic peptides are determined in a biological fluid from a person suffering from subjective or objectively detectable cognitive impairments, the resulting person-specific measurements are combined computationally to give a person-specific complex reference value, and conclusions are drawn concerning the presence of a neurodegenerative disorder in the person on the basis of the person-specific complex reference value found. | 03-11-2010 |
20100056763 | METHOD FOR THE SELECTIVE DETERMINATION OF PROCALCITONIN 1-116 FOR DIAGNOSTIC PURPOSES AND ANTIBODIES AND KITS FOR CARRYING OUT SUCH A METHOD - The present invention provides an immunodiagnostic method for determining procalcitonin and procalcitonin derivatives in a biological sample of a patient for diagnostic purposes, in particular in the monitoring and control of treatment and the monitoring of the progression of a local or systemic bacterial infection, inflammation, sepsis or neurodegenerative disease. In particular, the method detects molecular forms of procalcitonin, or procalcitonin partial peptides derived therefrom, having the amino acids alanine and proline (Ala-Pro, AP) in positions 1 and 2 of the amino terminus of the complete procalcitonin 1-116 (SEQ ID NO: 1.) Also disclosed are antibodies and kits for carrying out such a method. | 03-04-2010 |
20100047835 | DIAGNOSIS OF INFECTIONS OR INFLAMMATORY DISEASES OF THE AIRWAYS AND LUNGS ASSOCIATED WITH HEART FAILURE - The invention relates to a method for diagnosis of infections or inflammatory diseases of the airways and lungs with associated heart failure, wherein the marker procalcitonin or a partial sequence thereof is determined in a patient to be examined, in particular for classifying patients according to risk. The invention further relates to a diagnostic device and kit for carrying out the method. | 02-25-2010 |
20100041064 | DIAGNOSIS AND RISK STRATIFICATION OF INFECTIONS AND CHRONIC DISEASES OF THE RESPIRATORY TRACT AND LUNGS BY MEANS OF PROVASOPRESSIN, PARTICULARLY COPEPTIN OR NEUROPHYSIN II - The invention relates to a method for diagnosing and/or stratifying the risk of infections or chronic diseases of the respiratory tract and lungs, particularly lower respiratory tract infections and chronic obstructive pulmonary disease. In said method, provasopressin (proAVP) or fragments or partial peptides thereof, especially copeptin or neurophysin II, is/are determined. The invention further relates to suitable biomarker combinations for in-vitro diagnosis. | 02-18-2010 |
20100035289 | DIAGNOSIS AND RISK STRATIFICATION BY MEANS OF THE NOVEL MARKER CT-PROADM - The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No, 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method. | 02-11-2010 |
20100035286 | IN VITRO METHOD FOR THE DIAGNOSIS AND EARLY DIAGNOSIS OF NEURODEGENERATIVE DISORDERS - In vitro method for the detection and early detection of, for the determination of the degree of severity of, and for the assessment of the course of and prognosis of neurodegenerative disorders, in which an immunodiagnostic determination method is used to determine the apolipoprotein C-1 (Apo C-1) immunoreactivity in a serum or plasma sample from a patient suffering from subjective or objectively verifiable cognitive disorders. | 02-11-2010 |
20100035275 | DIAGNOSIS AND RISK ASSESSMENT OF PANCREATIC DIABETES USING MR-PROADM - The invention relates to a method for diagnosis and/or risk assessment of pancreatic diabetes, in particular of diabetic sequelae, wherein a determination of the marker mid-regional proAdrenomedullin (MR-proADM: SEQ ID No. 2) or a partial peptide or fragment thereof or if contained in a marker combination (Panel, Cluster) is carried out on a patient under investigation. The invention further relates to a diagnostic device and a kit for carrying out said method. | 02-11-2010 |
20100028921 | RISK STRATIFICATION FOR ACUTE CORONARY SYNDROME BY MEANS OF FRAGMENTS/PARTIAL PEPTIDES OF PROVASOPRESSIN, ESPECIALLY COPEPTIN OR NEUROPHYSIN II - The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis. | 02-04-2010 |
20090311719 | IN VITRO METHOD FOR DIAGNOSING NEURODEGENERATIVE DISEASES - Disclosed is an in vitro method for the detection, for the determination of the severity and for the assessment of the progress and prediction of neurodegenerative diseases, in which the presence and/or concentration of carbamoyl phosphate synthetase 1 (CPS 1) is determined in a biological fluid of a patient who suffers from a neurodegenerative disease or is suspected of suffering from such a disease, and conclusions about the presence, progression, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the determined presence and/or concentration of CPS 1 or the non-detectability of a CPS 1 immune reactivity. | 12-17-2009 |
20090311186 | METHOD FOR CONTROLLING THE THERAPY OF PATIENTS SUFFERING FROM CARDIAC INSUFFICIENCY BY MEANS OF IN VITRO DETERMINATION OF THRESHOLD VALUES OF VASOACTIVE PEPTIDES - Disclosed is a method for controlling the therapeutic treatment of a patient suffering from cardiac insufficiency. In said method, it is determined how the concentration of at least one of the vasoactive peptides adrenomedullin (ADM), endothelin-1 (ET-1), and/or vasopressin (AVP) changes in the patient's blood after beginning the therapy, and the therapeutic measures are considered to be unsatisfactory and are modified in case said concentration does not decrease at all or not enough in relation to a threshold value for the respective vasoactive peptide. | 12-17-2009 |
20090263822 | In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases - An in vitro process for the detection and early detection of neurodegenerative diseases, for determination of the severity, and to evaluate the progression of and render a prognoses of neurogenerative diseases, in a patient suffering from a subjectively or objectively detectable cognitive impairment, by determining the concentration of an analyte selected from natriuretic peptides, in particular ANP, and, if necessary, BNP and/or CNP in a biological fluid of the patient, whereby the determination of the analyte is performed directly and/or indirectly as the determination of a relevant co-peptide generated from a mutual propeptide, and is based upon the measured concentration of the determined analyte thus making it possible to form conclusions about a neurodegenerative disease or an early form typical of such a disease or the course of the disease and/or the success of the efforts to relieve or prevent the disease. | 10-22-2009 |
20090221009 | Diagnostic Method for Disorders Using Copeptin - The use of copeptin as diagnostic marker for the determination of the release of vasopressin, especially in connection with disorders associated with non-physiological alterations of vasopressin release from the neurohypophysis, especially for detection and early detection, diagnosing and monitoring of the course of cardiovascular diseases, renal and pulmonary diseases as well as shock, including septic shock, sepsis and diseases/disorders of the central nervous system and neurodegenerative diseases. | 09-03-2009 |
20090176267 | IN VITRO METHOD FOR THE IDENTIFICATION AND EARLY IDENTIFICATION AND FOR THE CONCOMITANT MONITORING OF THE THERAPY OF DRUG-AND ADDICTIVE SUBSTANCE-INDUCED LIVER DAMAGE - Disclosed is an in vitro method for the identification and the concomitant monitoring of the therapy and cure of drug-induced or addictive substance-induced liver damage, in which the occurrence of the human enzyme carbamoyl synthase 1 (CPS 1) or its concentration is determined in serum or plasma samples from patients who are being or have been treated with potentially liver-damaging drugs, or from people who take harmful stimulants and addictive substances or are exposed to hepatotoxic substances. | 07-09-2009 |
20090136973 | DETERMINATION OF SHORT-CHAIN SRL ALCOHOL DEHYDROGENASE (DHRS4) AS A BIOMARKER FOR INFLAMMATIONS AND INFECTIONS - The present invention relates to the use of short-chain SRL alcohol dehydrogenase (DHRS4, SEQ ID NO: 1) and peptides thereof as humoral biomarkers for the diagnostic detection and prognosis of the course, and also monitoring the course and therapy of septic inflammations and infections. | 05-28-2009 |
20090012268 | NOVEL MONOCLONAL THYROID STIMULATING OR BLOCKING ANTIBODIES, PEPTIDE SEQUENCES CORRESPONDING TO THEIR VARIABLE REGIONS, AND THEIR USES IN DIAGNOSTIC, PREVENTIVE AND THERAPEUTIC MEDICINE - Monoclonal antibodies (mAbs) having thyroid stimulating activity (TSAb), especially full or considerably agonistic activity, or thyroid blocking activity (TBAb), which are obtainable by genetic immunization of mice, or fragments (F(ab′) | 01-08-2009 |
20090011431 | Diagnosis of Sepsis by the Selective Determination of the Concentration of Cu/Zn Superoxide Dismutase (Cu/Zn Sod) in Patient Samples - The present invention relates to a method for the early determination of the risk of mortality of patients in intensive care units or emergency care units during which the concentration of Cu/Zn superoxide dismutase (Cu/Zn SOD) in a serum sample or plasma sample of the patient is selectively determined, and quantitatively or semi-quantitatively measured concentrations, which exceed a predetermined threshold value are correlated with a high risk of mortality. | 01-08-2009 |
20080261232 | Use of Precursors of Enkephalins and/or Their Fragments in Medical Diagnostics - The invention relates to the diagnosis of disease based on the presence of biochemical components in human or animal body fluids, tissues and/or biomaterials. More specifically the invention relates to the use of precursors of enkephalins and/or its fragments isolated from body fluids, tissues or other biomaterials as a marker peptide for detection of a number of diseases/disorders including diseases/disorders of the central nervous system, neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, Huntington's disease, ischemia including myocardiac ishcemica, schizophrenia, disease/disorders of the immune system, diseases/conditions of pain, chronic pain, migraine, tension type headache, tumor diseases/cancer including lymphoblastic leukaemia, malignant brain tumors, adenomas, in particular human pituitary adenomas, disorders of the blood brain barrier, multiple sclerosis, inflammation, chronic arthritis, infectious diseases, bacterial and viral infections, in particular infections of Gram-positive bacteria, borna diseases virus infections, peritonitis, intoxication, AIDS, stress, trauma comprising head trauma, infarction, in particular cerebral infarction, heart and cardiovascular diseases including coronary heart disease, bone and skin disorders, malaria chronic/obstructive pulmonary disease and cerebral damage. The invention further provides antibodies that bind to proenkephalin and its fragments. In accordance with the invention, a kit useful for the above mentioned diagnosis is also provided. | 10-23-2008 |
20080248509 | METHOD FOR DIAGNOSIS OF ALZHEIMER'S DISEASE WITH DETERMINATION OF LASP-1 IMMUNOREACTIVITY - Method for early diagnosis and diagnosis, for prognosis and assessment of the severity and for therapy-accompanying monitoring of inflammatory diseases and infections, in particular sepsis-like systemic infections and Alzheimer's disease, in which the presence and/or amount of the protein LASP-1 (SEQ ID NO:1) or of the protein LAP-1 (SEQ ID NO:16) or of an immunoreactive fragment of one of these proteins in free and/or protein-bound form is determined, preferably as immunoreactivity, in a biological fluid, or optionally a tissue sample, of a patient, and conclusions are drawn with respect to the presence, the expected course, the severity or the success of a therapy of the inflammatory disease or of the infection from the presence and/or amount of the proteins determined. | 10-09-2008 |
20080227751 | METHOD AND AGENT FOR THE PREVENTION, INHIBITION AND TREATMENT OF SEPSIS - The invention relates to the use of Asialo-G | 09-18-2008 |
20080206797 | Csf Diagnostic in Vitro Method for Diagnosis of Dementias and Neuroinflammatory Diseases - CSF diagnostic in vitro method for the diagnosis of dementias and neuroinflammatory diseases, in which a determination of the procalcitonin immunoreactivity (PCT immunoreactivity) is carried out in a sample of cerebrospinal fluid (CSF) of a patient who is suffering from a dementia or neuroinflammatory disease or is suspected of suffering from such a disease. Conclusions about the presence, the course, the severity or the success of a treatment of the dementia or neuroinflammatory disease are drawn from a measured PCT immunoreactivity which is above a threshold value typical for healthy individuals. | 08-28-2008 |
20080199966 | Vitro Method For the Diagnosis of Neurodegenerative Diseases - An in vitro method for the detection, determination of severity and monitoring and prognosis of neurodegenerative diseases is disclosed. The presence and/or concentration of the physiologically inactive proadrenomedullin (proADM) partial peptide, in particular, the midregional proADM partial peptide, is determined in a biological fluid of a patient who is suffering from a neurodegenerative disease or is suspected of having such a disease. Conclusions about the presence, course, severity or success of a treatment of the neurodegenerative disease are drawn on the basis of the presence and/or concentration of the specific partial peptide in the biological sample. | 08-21-2008 |